Medical masks versus N95 respirators for preventing COVID-19 among health care workers: a randomized trial
Author(s)
Type
Journal Article
Abstract
Background:
It is uncertain if medical masks offer similar protection against COVID-19 compared with N95 respirators.
Objective:
To determine whether medical masks are noninferior to N95 respirators to prevent COVID-19 in health care workers providing routine care.
Design:
Multicenter, randomized, noninferiority trial. (ClinicalTrials.gov: NCT04296643).
Setting:
29 health care facilities in Canada, Israel, Pakistan, and Egypt from 4 May 2020 to 29 March 2022.
Participants:
1009 health care workers who provided direct care to patients with suspected or confirmed COVID-19.
Intervention:
Use of medical masks versus fit-tested N95 respirators for 10 weeks, plus universal masking, which was the policy implemented at each site.
Measurements:
The primary outcome was confirmed COVID-19 on reverse transcriptase polymerase chain reaction (RT-PCR) test.
Results:
In the intention-to-treat analysis, RT-PCR–confirmed COVID-19 occurred in 52 of 497 (10.46%) participants in the medical mask group versus 47 of 507 (9.27%) in the N95 respirator group (hazard ratio [HR], 1.14 [95% CI, 0.77 to 1.69]). An unplanned subgroup analysis by country found that in the medical mask group versus the N95 respirator group RT-PCR–confirmed COVID-19 occurred in 8 of 131 (6.11%) versus 3 of 135 (2.22%) in Canada (HR, 2.83 [CI, 0.75 to 10.72]), 6 of 17 (35.29%) versus 4 of 17 (23.53%) in Israel (HR, 1.54 [CI, 0.43 to 5.49]), 3 of 92 (3.26%) versus 2 of 94 (2.13%) in Pakistan (HR, 1.50 [CI, 0.25 to 8.98]), and 35 of 257 (13.62%) versus 38 of 261 (14.56%) in Egypt (HR, 0.95 [CI, 0.60 to 1.50]). There were 47 (10.8%) adverse events related to the intervention reported in the medical mask group and 59 (13.6%) in the N95 respirator group.
Limitation:
Potential acquisition of SARS-CoV-2 through household and community exposure, heterogeneity between countries, uncertainty in the estimates of effect, differences in self-reported adherence, differences in baseline antibodies, and between-country differences in circulating variants and vaccination.
Conclusion:
Among health care workers who provided routine care to patients with COVID-19, the overall estimates rule out a doubling in hazard of RT-PCR–confirmed COVID-19 for medical masks when compared with HRs of RT-PCR–confirmed COVID-19 for N95 respirators. The subgroup results varied by country, and the overall estimates may not be applicable to individual countries because of treatment effect heterogeneity.
Primary Funding Source:
Canadian Institutes of Health Research, World Health Organization, and Juravinski Research Institute.
It is uncertain if medical masks offer similar protection against COVID-19 compared with N95 respirators.
Objective:
To determine whether medical masks are noninferior to N95 respirators to prevent COVID-19 in health care workers providing routine care.
Design:
Multicenter, randomized, noninferiority trial. (ClinicalTrials.gov: NCT04296643).
Setting:
29 health care facilities in Canada, Israel, Pakistan, and Egypt from 4 May 2020 to 29 March 2022.
Participants:
1009 health care workers who provided direct care to patients with suspected or confirmed COVID-19.
Intervention:
Use of medical masks versus fit-tested N95 respirators for 10 weeks, plus universal masking, which was the policy implemented at each site.
Measurements:
The primary outcome was confirmed COVID-19 on reverse transcriptase polymerase chain reaction (RT-PCR) test.
Results:
In the intention-to-treat analysis, RT-PCR–confirmed COVID-19 occurred in 52 of 497 (10.46%) participants in the medical mask group versus 47 of 507 (9.27%) in the N95 respirator group (hazard ratio [HR], 1.14 [95% CI, 0.77 to 1.69]). An unplanned subgroup analysis by country found that in the medical mask group versus the N95 respirator group RT-PCR–confirmed COVID-19 occurred in 8 of 131 (6.11%) versus 3 of 135 (2.22%) in Canada (HR, 2.83 [CI, 0.75 to 10.72]), 6 of 17 (35.29%) versus 4 of 17 (23.53%) in Israel (HR, 1.54 [CI, 0.43 to 5.49]), 3 of 92 (3.26%) versus 2 of 94 (2.13%) in Pakistan (HR, 1.50 [CI, 0.25 to 8.98]), and 35 of 257 (13.62%) versus 38 of 261 (14.56%) in Egypt (HR, 0.95 [CI, 0.60 to 1.50]). There were 47 (10.8%) adverse events related to the intervention reported in the medical mask group and 59 (13.6%) in the N95 respirator group.
Limitation:
Potential acquisition of SARS-CoV-2 through household and community exposure, heterogeneity between countries, uncertainty in the estimates of effect, differences in self-reported adherence, differences in baseline antibodies, and between-country differences in circulating variants and vaccination.
Conclusion:
Among health care workers who provided routine care to patients with COVID-19, the overall estimates rule out a doubling in hazard of RT-PCR–confirmed COVID-19 for medical masks when compared with HRs of RT-PCR–confirmed COVID-19 for N95 respirators. The subgroup results varied by country, and the overall estimates may not be applicable to individual countries because of treatment effect heterogeneity.
Primary Funding Source:
Canadian Institutes of Health Research, World Health Organization, and Juravinski Research Institute.
Date Issued
2022-12
Date Acceptance
2022-12-01
Citation
Annals of Internal Medicine, 2022, 175 (12), pp.1629-1638
ISSN
0003-4819
Publisher
American College of Physicians
Start Page
1629
End Page
1638
Journal / Book Title
Annals of Internal Medicine
Volume
175
Issue
12
Copyright Statement
© 2022 American College of Physicians
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000955829100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
General & Internal Medicine
INFECTION
Life Sciences & Biomedicine
Medicine, General & Internal
PERSONAL PROTECTIVE EQUIPMENT
RISK
Science & Technology
Publication Status
Published
OA Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707441/
Date Publish Online
2022-12-01